Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 2
1990 1
1991 2
1992 9
1993 2
1994 5
1995 1
1996 1
1997 2
2000 3
2001 4
2003 1
2004 1
2005 2
2006 4
2007 5
2008 7
2009 7
2010 8
2011 7
2012 19
2013 14
2014 23
2015 22
2016 25
2017 28
2018 21
2019 21
2020 41
2021 40
2022 42
2023 26
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

358 results

Results by year

Filters applied: . Clear all
Page 1
β-Hydroxybutyrate suppresses colorectal cancer.
Dmitrieva-Posocco O, Wong AC, Lundgren P, Golos AM, Descamps HC, Dohnalová L, Cramer Z, Tian Y, Yueh B, Eskiocak O, Egervari G, Lan Y, Liu J, Fan J, Kim J, Madhu B, Schneider KM, Khoziainova S, Andreeva N, Wang Q, Li N, Furth EE, Bailis W, Kelsen JR, Hamilton KE, Kaestner KH, Berger SL, Epstein JA, Jain R, Li M, Beyaz S, Lengner CJ, Katona BW, Grivennikov SI, Thaiss CA, Levy M. Dmitrieva-Posocco O, et al. Nature. 2022 May;605(7908):160-165. doi: 10.1038/s41586-022-04649-6. Epub 2022 Apr 27. Nature. 2022. PMID: 35477756 Free PMC article.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
Among patients with CPS of 10 or more, median progression-free survival was 9.7 months with pembrolizumab-chemotherapy and 5.6 months with placebo-chemotherapy (hazard ratio [HR] for progression or death, 0.65, 95% CI 0.49-0.86; one-sided p=0.0012 [primary objective met]). …
Among patients with CPS of 10 or more, median progression-free survival was 9.7 months with pembrolizumab-chemotherapy and 5.6 months with p …
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
FINDINGS: Among women with ER-positive disease, allocation to continue tamoxifen reduced the risk of breast cancer recurrence (617 recurrences in 3428 women allocated to continue vs 711 in 3418 controls, p=0.002), reduced breast cancer mortality (331 deaths vs 397 deaths, …
FINDINGS: Among women with ER-positive disease, allocation to continue tamoxifen reduced the risk of breast cancer recurrence (617 recurrenc …
Oral Nutritional Supplementation Improves Growth in Children at Malnutrition Risk and with Picky Eating Behaviors.
Khanna D, Yalawar M, Saibaba PV, Bhatnagar S, Ghosh A, Jog P, Khadilkar AV, Kishore B, Paruchuri AK, Pote PD, Mandyam RD, Shinde S, Shah A, Huynh DTT. Khanna D, et al. Nutrients. 2021 Oct 14;13(10):3590. doi: 10.3390/nu13103590. Nutrients. 2021. PMID: 34684591 Free PMC article. Clinical Trial.
From day 1 to day 90, study findings showed significant increases in weight-for-height percentile for ONS1 + DC and for ONS2 + DC interventions, as compared to DC only (p = 0.0086 for both). There was no significant difference between the two ONS groups. Anthropometric mea …
From day 1 to day 90, study findings showed significant increases in weight-for-height percentile for ONS1 + DC and for ONS2 + DC interventi …
Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ; NorthStar UK Network and CINRG DNHS Investigators. Mah JK, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2144178. doi: 10.1001/jamanetworkopen.2021.44178. JAMA Netw Open. 2022. PMID: 35076703 Free PMC article. Clinical Trial.
There were no statistically significant differences between participants receiving higher-dose vamorolone and matched participants in the historical control groups receiving glucocorticoid treatment (75 patients in DNHS and 110 patients in NSUK) over a 2-year period in NSAA total …
There were no statistically significant differences between participants receiving higher-dose vamorolone and matched participants in the hi …
Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study.
Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, Adhikari P, Rao PV, Saboo B, Kumar A, Bhansali A, John M, Luaia R, Reang T, Ningombam S, Jampa L, Budnah RO, Elangovan N, Subashini R, Venkatesan U, Unnikrishnan R, Das AK, Madhu SV, Ali MK, Pandey A, Dhaliwal RS, Kaur T, Swaminathan S, Mohan V; ICMR–INDIAB Collaborative Study Group. Anjana RM, et al. Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596. doi: 10.1016/S2213-8587(17)30174-2. Epub 2017 Jun 7. Lancet Diabetes Endocrinol. 2017. PMID: 28601585
The prevalence of diabetes varied from 4.3% in Bihar (95% CI 3.7-5.0) to 10.0% (8.7-11.2) in Punjab and was higher in urban areas (11.2%, 10.6-11.8) than in rural areas (5.2%, 4.9-5.4; p<0.0001) and higher in mainland states (8.3%, 7.9-8.7) than in the northeast (5.9%, …
The prevalence of diabetes varied from 4.3% in Bihar (95% CI 3.7-5.0) to 10.0% (8.7-11.2) in Punjab and was higher in urban areas (11.2%, 10 …
Reply to Marieke J. Krimphove, Junaid Nabi, Alexander P. Cole, and Quoc-Dien Trinh's Letter to the Editor re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. J Clin Oncol 2018;36:1192-8.
Ennis RD, Hu L, Ryemon SN, Lin J, Mazumdar M. Ennis RD, et al. Eur Urol Oncol. 2019 Mar;2(2):226-227. doi: 10.1016/j.euo.2018.08.025. Epub 2018 Sep 21. Eur Urol Oncol. 2019. PMID: 31017102 No abstract available.
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P; International Polycap Study 3 Investigators. Yusuf S, et al. N Engl J Med. 2021 Jan 21;384(3):216-228. doi: 10.1056/NEJMoa2028220. Epub 2020 Nov 13. N Engl J Med. 2021. PMID: 33186492 Free PMC article. Clinical Trial.
358 results